

Public Comments on
Peer Review of the BG1Luc ER TA Assay
SACATM
June 16 – 17, 2011

Catherine Willett, PhD
Associate Director
Regulatory Testing
People for the Ethical Treatment of Animals

Supported recommendations

Main finding: the Lumi-Cell (BG₁Luc) ER TA test method is a scientifically valid method for assessing the *in vitro* estrogen agonist and antagonist activity of compounds within a test battery or tiered testing scheme

Supported recommendations

Other recommendations:

- the BG1Luc ER TA test be considered as an alternative for
 - (CER1 STTA) and the
 - rat uterine cytosol (RUC) ER binding assay
 - (positives be confirmed using a pure ER antagonist)
- recombinant ER binding assays to replace the RUC ER assay
- development and use of a metabolism component is critical
- data evaluation should include potency evaluations
 - quantification of activity
 - relative to known reference substances
 - including associated uncertainty
- evaluate the quality of the data used to classify ICCVAM reference substances
- discuss the use of the assay within the context of EPA's Endocrine Disruptor Testing Program (EDSP)
- Consider other potential uses that would reduce animal use

Additional recommendations

Evaluate and update chemical reference list:

- Panel recommendation to evaluate the quality of data used to characterize reference chemicals
- Follow-up by:
 - revising chemical list
 - adding new information to searchable public database (e.g. ToxRefDB)

Ensure that the best characterized chemicals are used for future assay evaluations

Identify new reference chemicals in underrepresented chemical classes

Additional recommendations

Considerations of use to reduce animal testing:

- In addition to screening and prioritization
- Revising structure of EDSP Tier 1
 - *In vitro* assessment prior to animal testing
- Weight-of-evidence (WoE) approach
 - reduce or eliminate ER-related animal tests
 - uterotrophic
 - rat pubertal
 - fish short-term reproduction

Additional recommendations

Quantitative Comparison to CERI STTA:

- Panel recommendation to evaluate data quantitatively
 - relative to reference chemical
 - Relative Potency Index (in addition to EC₅₀)
- Allows direct comparison between assays that may use different assessment methods and decision criteria
 - e.g. CERI STTA assay
 - Uterotrophic - ?

Additional recommendations

Length of Time to Complete Study :

- Review took seven years
- BG₁Luc ER TA not included initial phase(s) of the EDSP
- More efficient process needed in light of large number of new assays

Panel report should include:

- issues that contributed to the length of the review
- recommendations for avoiding these issues in future reviews

Thank you